BD completed the acquisition of Edwards Lifesciences' Critical Care product group on September 3, 2024, for $3.911 billion, renaming it BD Advanced Patient Monitoring. This acquisition expands BD's portfolio of smart connected care solutions.

BD's strategy emphasizes innovation in smart devices, robotics, analytics, and AI to enable new care settings and improve outcomes. The company is also focusing on strategic acquisitions in faster-growing market segments.

BD completed the sale of the Interventional segment's Surgical Instrumentation platform in August 2023, recognizing a pre-tax gain of approximately $268 million. This divestiture is part of BD's strategy to focus on core businesses.

BD is focused on driving operating effectiveness and margin expansion through the BD Excellence program, which aims to increase factory productivity and asset efficiencies. This indicates a focus on operational improvements.

BD is making strategic investments to prioritize a culture of quality and enhance customer experiences through digitalization of internal processes and go-to-market approaches, showing a commitment to improving operations and customer satisfaction.

BD is collaborating across its supply chain to responsibly source materials and goods, as well as to reduce environmental impacts, and is continuing investments in an enterprise-wide renewable energy strategy, demonstrating a focus on both operational and environmental improvements.

The company acknowledges that global economic downturns, inflation, and supply chain disruptions may impact demand, prices, and the ability to produce products, highlighting potential risks to future performance.

BD's foreign operations are subject to commercial, political, and financial risks, including currency fluctuations, instability, and changes in trade agreements, indicating potential challenges in international markets.

The company recognizes the risks related to cybersecurity incidents and breaches, which could impair the ability to conduct business, compromise information, and result in regulatory actions, highlighting a significant operational risk.

BD faces significant competition from a wide range of existing competitors and new market entrants, including large medical device companies and specialized firms, indicating a highly competitive environment.

The medical technology industry is subject to rapid technological change and evolving customer preferences, including demand for sustainable products and digital capabilities, highlighting the need for continuous innovation to maintain competitiveness.

The medical technology industry has experienced significant consolidation, resulting in companies with greater scale and market presence, increasing competition among medical device suppliers.

The company's results of operations could be negatively impacted by volatility in the cost of raw materials, components, labor, freight, energy and other production costs, highlighting a risk to profitability.

A reduction or interruption in the supply of certain raw materials and components, some of which are sole-sourced, could adversely affect the company's ability to manufacture and sell products, indicating a vulnerability in the supply chain.

The company's manufacturing and sterilization operations are subject to interruptions from various factors, including system outages, regulatory requirements, and natural disasters, highlighting a potential operational risk.

BD is accelerating innovation in areas such as smart devices, robotics, analytics, and artificial intelligence to enable new care settings, improve outcomes, and streamline care workflows, indicating a strong focus on technological advancement.

The company is investing in research and development to expand category leadership and develop a robust product pipeline, highlighting the importance of innovation for future growth.

BD owns significant intellectual property, including patents, trade secrets, and trademarks, which are of material importance to the business, indicating a reliance on protecting its innovations.

The company paid cash dividends to common shareholders of $1.100 billion in 2024, demonstrating a commitment to returning value to shareholders through dividends.

The company's capital expenditures of $725 million in 2024 are primarily focused on projects that enhance cost structure and manufacturing capabilities, indicating strategic investments in operational improvements.

The company executed and settled accelerated share repurchase agreements for the repurchase of 2.118 million shares of its common stock for a total consideration of $500 million, indicating a commitment to returning capital to shareholders.

BD has a commitment to global inclusion, diversity, and equity, with annual goals focused on fostering an inclusive workplace, and executive leaders sponsoring Associate Resource Groups, indicating a focus on social responsibility.

The company is investing over $2 million across more than 25 communities through the BD Community Investment Fund, demonstrating a commitment to addressing healthcare equity and social determinants of health.

BD is focused on reducing environmental impacts by collaborating across the supply chain to responsibly source materials and goods, and by continuing investments in an enterprise-wide renewable energy strategy, indicating a commitment to sustainability.

The company notes that market dynamics in China, such as volume-based procurement programs, had an adverse impact on results of operations, indicating challenges in the Chinese market.

The transition of healthcare delivery from acute to non-acute settings is placing additional financial pressure on hospitals and the broader healthcare system, which could impact the demand for BD's products and services.

Reductions or delays in governmental research funding and higher interest rates could cause customers for BD's instruments and reagents to delay or forgo purchases of these products, highlighting a potential risk to revenue.